Photo from Novartis' Indianapolis plant (Credit: Novartis)
Novartis adds Indianapolis site to its manufacturing capacity for radioligand drug Pluvicto
Novartis has the go-ahead from the FDA to manufacture its radiopharmaceutical Pluvicto at a new facility in Indianapolis, marking a step toward addressing burgeoning demand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.